Ioscani Jiménez del Val

This paper combines metabolic and cellular glycoengineering to control mAb β1,4-galactosylation, achieving broad tunable control and improved pharmacological activity.

This paper describes a dual genetic engineering strategy to enhance mAb β4-galactosylation in CHO cells, achieving over 90% galactosylation and reducing Man5 glycans without affecting mAb titre.

This study evaluates lectin-based surface profiling as a predictor of mAb product glycosylation in CHO cells following targeted glycogene engineering.

The paper introduces CHOmpact, a reduced metabolic model of CHO cells that improves interpretability and physiological consistency compared to large-scale models.